Cj Pollet
Optometrist · Mandeville, LANPI 1700846581
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,076 of the $7,648 with a category attached, or 79.4%. It is spread thinly across 19 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,971 and has fallen 68.4% since, to $623 in 2025. Among optometrist clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 210 payments — averaging $36.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- Alcon$960
- Johnson & Johnson Vision Care, Inc.$945
- Oyster Point Pharma, Inc.$634
- Coopervision Inc.$601
- Bausch & Lomb Americas Inc.$499
- plus $2K from 13 others
What the payments were for
- Travel & lodging$1,41619%
- Food & beverage$6,07679%
- Entertainment$1562%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 25 | $1,807 |
| Alcon | 24 | $960 |
| Johnson & Johnson Vision Care, Inc. | 33 | $945 |
| Oyster Point Pharma, Inc. | 29 | $634 |
| Coopervision Inc. | 16 | $601 |
| Bausch & Lomb Americas Inc. | 16 | $499 |
| AbbVie(2 entities) | 25 | $378 |
| Sun Pharmaceutical Industries Inc. | 9 | $363 |
| Kala Pharmaceuticals, Inc. | 8 | $253 |
| Rxsight Inc | 2 | $240 |
| Dompe US, Inc. | 9 | $226 |
| Optos, Inc. | 2 | $156 |
| Tarsus Pharmaceuticals, Inc. | 5 | $153 |
| Maculogix, Inc. | 1 | $124 |
| LKC Technologies, Inc. | 1 | $119 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $118 |
| Novartis | 2 | $37 |
| Biotissue Holdings Inc. | 1 | $19 |
| Beaver-visitec International, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ULTRA$1,226
- BIOTRUE$1,211
- PANORAMIC OPHTHALMOSCOPE$259
- OCT OPHTHALMOSCOPE$259
- Precision 1$244
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$240
- Tecnis Simplicity$235
- Clariti Contact Lens$227
- Acuvue$224
- INFUSE$219
- CEQUA$208
- NFC-700$130
- AdaptDx$124
- Tecnis IOL$118
- VERITAS Vision System$118
- XDEMVY$116
- MyDay Contact Lens$108
- TOTAL30$106
How this compares
$7,648 in reported general payments places this provider in the 95th percentile of 500 optometrist providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 50 | $60,346 |
| XdemvyLotilaner | 22 | $39,661 |
| XiidraLifitegrast | 17 | $30,550 |
| TyrvayaVarenicline Tartrate | 21 | $30,311 |
| LumiganBimatoprost | 45 | $20,669 |
| CequaCyclosporine | 13 | $11,742 |
| CombiganBrimonidine Tartrate/Timolol | 31 | $10,349 |
| MieboPerfluorohexyloctane/Pf | 12 | $8,885 |
| Fluorometholone | 29 | $1,937 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $1,522 |
| Prednisolone Acetate | 37 | $1,150 |
| Latanoprost | 42 | $571 |
| Timolol Maleate | 21 | $278 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 16 | $221 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $378 | $91,364126 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $153 | $39,66122 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $499 | $39,43529 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $634 | $30,31121 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $363 | $11,74213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 500 optometrist providers in Louisiana.
Other optometrist in Mandeville
- Pamela TheriotShreveport$207K
- Joshua DavidsonGonzales$189K
- Jeffrey WilhiteMarrero$86K
- Christopher WrotenHammond$59K
- James LamarNew Orleans$45K
- John McCallLogansport$32K
- Robert KellyMarrero$26K
- Shane FontenotJennings$23K
- Stephen LewisShreveport$17K
- Breanne McGheeNew Orleans$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.